Design and synthesis of 2-Substituted-4-benzyl-5-methylimidazoles as new potential Anti-breast cancer agents to inhibit oncogenic STAT3 functions
作者:Botros Y. Beshay、Amira A. Abdellatef、Yasser M. Loksha、Salwa M. Fahmy、Nargues S. Habib、Alaa El-Din A. Bekhit、Paris E. Georghiou、Yoshihiro Hayakawa、Adnan A. Bekhit
DOI:10.1016/j.bioorg.2021.105033
日期:2021.8
imidazole-bearing compounds showed greater STAT3 inhibition than their lead compounds VS1 and the oxadiazole derivative MD77. Within all tested compounds, ten derivatives effectively inhibited the growth of the two tested breast cancer cells with IC50 values ranging from 6.66 to 26.02 µM. In addition, the most potent derivatives 2a and 2d inhibited the oncogenic function of STAT3 as seen in the inhibition
已知 STAT3 信号转导与肿瘤发生相关,并且进一步的癌细胞内在激活 STAT3 会导致对几种致癌过程的调节发生改变。鉴于 STAT3 在癌症发展和进展中的重要性,尤其是乳腺癌,发现 STAT3 抑制剂的新化学实体以开发抗乳腺癌候选药物至关重要。在此,4-benzyl-2-benzylthio-5-methyl-1 H - imidazole ( 2a ) 和 4-benzyl-5-methyl-2-[(2,6-difluorobenzyl)thio]-1 H- imidazole ( 2d)) 来自一组 30 个含咪唑的化合物显示出比它们的先导化合物 VS1 和恶二唑衍生物 MD77 更大的 STAT3 抑制。在所有测试化合物中,十种衍生物有效抑制了两种测试乳腺癌细胞的生长,IC 50值范围为 6.66 至 26.02 µM。此外,最有效的衍生物2a和2d抑制 STAT3 的致癌功能,如抑制乳腺癌细胞系的集落形成和